These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21832017)

  • 21. The antigenic drift molecular basis of the H5N1 influenza viruses in a novel branch of clade 2.3.4.
    Zhong L; Zhao Q; Zhao K; Wang X; Zhao G; Li Q; Gu M; Peng D; Liu X
    Vet Microbiol; 2014 Jun; 171(1-2):23-30. PubMed ID: 24745625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
    Tan Y; Ng Q; Jia Q; Kwang J; He F
    J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtype H5N1 viruses in China.
    Li Z; Ma C; Liu Z; He W
    Immunol Lett; 2011 Mar; 135(1-2):59-63. PubMed ID: 20923686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines.
    Ohshima N; Iba Y; Kubota-Koketsu R; Yamasaki A; Majima K; Kurosawa G; Hirano D; Yoshida S; Sugiura M; Asano Y; Okuno Y; Kurosawa Y
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies.
    Kaverin NV; Rudneva IA; Govorkova EA; Timofeeva TA; Shilov AA; Kochergin-Nikitsky KS; Krylov PS; Webster RG
    J Virol; 2007 Dec; 81(23):12911-7. PubMed ID: 17881439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Monoclonal antibodies to highly pathogenic avian influenza A(H5N1) strain isolated in the Russian Federation: development and properties].
    Kushch AA; Klimova RR; Masalova OV; Fedorova NE; Botikov AG; Fediakina IT; Burtseva EI; Isaeva EI; Deriabin PG; L'vov DK
    Vopr Virusol; 2008; 53(5):9-14. PubMed ID: 19069786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-dimensional antigenic dendrogram and phylogenetic tree of avian influenza virus H5N1.
    Lai AC; Wu WL; Lau SY; Guan Y; Chen H
    FEMS Immunol Med Microbiol; 2012 Mar; 64(2):205-11. PubMed ID: 22066850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.
    Ross TM; DiNapoli J; Giel-Moloney M; Bloom CE; Bertran K; Balzli C; Strugnell T; Sá E Silva M; Mebatsion T; Bublot M; Swayne DE; Kleanthous H
    Vaccine; 2019 Apr; 37(17):2369-2376. PubMed ID: 30905528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
    Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
    Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of monoclonal antibodies to highly pathogenic avian influenza H5N1 virus and their application to diagnostics, prophylaxis, and therapy.
    Masalova OV; Klimova RR; Chichev EV; Fediakina IT; Loginova SY; Borisevich SV; Bondarev VP; Deryabin PG; Lvov DK; Kushch AA
    Acta Virol; 2011; 55(1):3-14. PubMed ID: 21434700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains.
    Fazekas G; Martosne-Mendi R; Jankovics I; Szilvasy I; Vajo Z
    Clin Vaccine Immunol; 2009 Apr; 16(4):437-43. PubMed ID: 19020111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses.
    Oh S; Selleck P; Temperton NJ; Chan PK; Capecchi B; Manavis J; Higgins G; Burrell CJ; Kok T
    J Virol Methods; 2009 May; 157(2):161-7. PubMed ID: 19152810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sparse serological evidence of H5N1 avian influenza virus infections in domestic cats, northeastern China.
    Sun L; Zhou P; He S; Luo Y; Jia K; Fu C; Sun Y; He H; Tu L; Ning Z; Yuan Z; Wang H; Li S; Yuan L
    Microb Pathog; 2015 May; 82():27-30. PubMed ID: 25752867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.
    Murakami S; Iwasa A; Iwatsuki-Horimoto K; Ito M; Kiso M; Kida H; Takada A; Nidom CA; Mai le Q; Yamada S; Imai H; Sakai-Tagawa Y; Kawaoka Y; Horimoto T
    Vaccine; 2008 Nov; 26(50):6398-404. PubMed ID: 18804131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.